Prognostic and predictive factors, such as estrogen/progesterone receptor (ER/PR) status and HER-2/neu gene amplification, serve as effective therapeutic targets for hormonal therapy in breast cancer patients [2,3]. This evidence concerns the gene ERBB2 and breast carcinoma.